| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 6246945 | Transplantation Proceedings | 2016 | 5 Pages |
Abstract
Post-transplantation CMV disease continues to be challenging to manage, and there is little consensus on optimal management strategies in this patient group, with a significant requirement for novel therapies; these may be pharmacologic or cell based. Extensive multidisciplinary discussion is important for most cases, but particularly for those patients who acquire virologic resistance.
Related Topics
Health Sciences
Medicine and Dentistry
Surgery
Authors
T. Ambrose, L.M. Sharkey, J. Louis-Auguste, C.S. Rutter, S. Duncan, S. English, E. Gkrania-Klotsas, A. Carmichael, J.M. Woodward, N. Russell, D. Massey, A. Butler, S. Middleton,